vs

Side-by-side financial comparison of Ategrity Specialty Insurance Co Holdings (ASIC) and Bioceres Crop Solutions Corp. (BIOX). Click either name above to swap in a different company.

Ategrity Specialty Insurance Co Holdings is the larger business by last-quarter revenue ($116.1M vs $77.6M, roughly 1.5× Bioceres Crop Solutions Corp.). Ategrity Specialty Insurance Co Holdings runs the higher net margin — 19.5% vs -9.6%, a 29.1% gap on every dollar of revenue.

Ategrity Specialty Insurance Co Holdings is a specialty insurance holding company that provides commercial property and casualty insurance solutions. It primarily focuses on excess and surplus lines coverage, serving niche segments including construction, healthcare, and small business markets across the United States, offering tailored policies for unique, hard-to-place risks that standard carriers do not typically cover.

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

ASIC vs BIOX — Head-to-Head

Bigger by revenue
ASIC
ASIC
1.5× larger
ASIC
$116.1M
$77.6M
BIOX
Higher net margin
ASIC
ASIC
29.1% more per $
ASIC
19.5%
-9.6%
BIOX

Income Statement — Q3 FY2025 vs Q1 FY2026

Metric
ASIC
ASIC
BIOX
BIOX
Revenue
$116.1M
$77.6M
Net Profit
$22.7M
$-7.4M
Gross Margin
46.8%
Operating Margin
25.6%
9.3%
Net Margin
19.5%
-9.6%
Revenue YoY
-16.8%
Net Profit YoY
-20.2%
EPS (diluted)
$0.45
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASIC
ASIC
BIOX
BIOX
Q3 25
$116.1M
$77.6M
Q2 25
$101.8M
Q1 25
$60.6M
Q4 24
$98.8M
Q3 24
$93.3M
Q1 24
$84.0M
Q4 23
$140.2M
Q3 23
$116.6M
Net Profit
ASIC
ASIC
BIOX
BIOX
Q3 25
$22.7M
$-7.4M
Q2 25
$17.6M
Q1 25
$-1.6M
Q4 24
$605.2K
Q3 24
$-6.2M
Q1 24
$9.8M
Q4 23
$1.2M
Q3 23
$-2.7M
Gross Margin
ASIC
ASIC
BIOX
BIOX
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q1 24
50.8%
Q4 23
36.7%
Q3 23
38.6%
Operating Margin
ASIC
ASIC
BIOX
BIOX
Q3 25
25.6%
9.3%
Q2 25
21.9%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q1 24
15.7%
Q4 23
12.0%
Q3 23
4.5%
Net Margin
ASIC
ASIC
BIOX
BIOX
Q3 25
19.5%
-9.6%
Q2 25
17.3%
Q1 25
-2.6%
Q4 24
0.6%
Q3 24
-6.6%
Q1 24
11.6%
Q4 23
0.9%
Q3 23
-2.3%
EPS (diluted)
ASIC
ASIC
BIOX
BIOX
Q3 25
$0.45
$-0.12
Q2 25
$0.39
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q1 24
$0.14
Q4 23
$0.00
Q3 23
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASIC
ASIC
BIOX
BIOX
Cash + ST InvestmentsLiquidity on hand
$34.3M
$15.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$588.6M
$288.3M
Total Assets
$1.4B
$734.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASIC
ASIC
BIOX
BIOX
Q3 25
$34.3M
$15.5M
Q2 25
$23.5M
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q1 24
$16.4M
Q4 23
$24.4M
Q3 23
$28.4M
Stockholders' Equity
ASIC
ASIC
BIOX
BIOX
Q3 25
$588.6M
$288.3M
Q2 25
$559.7M
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
Q1 24
$348.5M
Q4 23
$335.3M
Q3 23
$332.6M
Total Assets
ASIC
ASIC
BIOX
BIOX
Q3 25
$1.4B
$734.9M
Q2 25
$1.4B
Q1 25
$798.2M
Q4 24
$835.2M
Q3 24
$827.3M
Q1 24
$836.1M
Q4 23
$819.5M
Q3 23
$819.7M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASIC
ASIC
BIOX
BIOX
Operating Cash FlowLast quarter
$41.1M
$14.4M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.81×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASIC
ASIC
BIOX
BIOX
Q3 25
$41.1M
$14.4M
Q2 25
$50.8M
Q1 25
$23.3M
Q4 24
$-5.4M
Q3 24
$5.2M
Q1 24
$-17.4M
Q4 23
$21.1M
Q3 23
$14.7M
Cash Conversion
ASIC
ASIC
BIOX
BIOX
Q3 25
1.81×
Q2 25
2.88×
Q1 25
Q4 24
-8.85×
Q3 24
Q1 24
-1.78×
Q4 23
17.05×
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons